| 摘要 |
<p>The invention is based on the discovery that Mycoplasma hyorhinis (e.g., designated ATCC &num; PTA-3681) underlies the pathology of scleroderma and other autoimmune diseases. The invention encompasses Mycoplasma hyorhinis nucleic acid and polypeptides, methods of treating scleroderma and other autoimmune diseases by treating the underlying mycoplasma infection, compositions useful in treating scleroderma and other autoimmune diseases, methods of producing model organisms infected by mycoplasma, and a novel isolated strain of Mycoplasma hyorhinis designated ATCC &num; PTA-3681.</p> |
